STADA Arzneimittel AG — Earnings Release 2002

May 14, 2002

News Details

Ad-hoc | 14 May 2002 08:02

STADA Arzneimittel AG english

STADA: Q1 earnings surpass expectations Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA Arzneimittel AG increased its group sales in the three core segments of generics, branded products and special pharmaceuticals in the first three months of the fiscal year 2002 by +23% over the first quarter of 2001, to EUR 129.8 million. Group sales overall were up by +13% to EUR 152.7 million. The earnings index EBITDA reached EUR 26.1 million (+20%) in this period. Pre-tax profits for the first three months of 2002 were EUR 18.9 million (+21%), after-tax earnings were EUR 11.1 million (+23%), and earnings per share were EUR 0.596 (+19%). Results for the 1st quarter, which are reported for the first time according to IAS instead of HGB (with the figures for the prior year adjusted to match), are thus higher than expected. The Executive Board had forecast total sales growth of +15% to +20% in the core segments for 2002 as a whole, and at least double-digit percentage growth in earnings. In detailed terms the three core segments grew as follows in the 1st quarter of 2002: generics by +28%, branded products by +7% and special pharmaceuticals by +38%; non-core activities in the commercial business (-24%) were reduced according to plan. At the same time, the core segments have already been strengthened further in the current fiscal year with acquisitions in the USA, Italy and Spain. Despite a high equity ratio of 49.1%, the Executive Board and the Supervisory Board will recommend a reserve resolution to the shareholders meeting on 6/25/2002 that EUR 24.3 million in new capital be approved in order to expand the financial leeway for further growth of the company. In addition, the purchase of up to 10% of the capital stock in own shares will be proposed again to the shareholders meeting, after the time limit for the authorization to purchase own shares expires. The complete quarterly report can be found on the Internet at www.stada.de. For further information please contact: STADA Arzneimittel AG / Corporate Communications / D-61118 Bad Vilbel Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communication@stada.de or visit our website at http://www.stada.de end of ad-hoc-announcement (c)DGAP 14.05.2002 ——————————————————————————– WKN: 725180; ISIN: DE0007251803; Index: MDAX Listed: Amtlicher Handel in Frankfurt und Düsseldorf; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart 140802 Mai 02